scholarly journals Differential expression of aquaporin 5 and aquaporin 3 in squamous cell carcinoma and adenoid cystic carcinoma

2012 ◽  
Author(s):  
Shunsuke Ishimoto
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Adenoid Cystic Carcinoma ◽  
Differential Expression ◽  
Squamous Cell ◽  
Aquaporin 5 ◽  
Aquaporin 3 ◽  
Adenoid Cystic

Characteristic findings of adenoid cystic carcinoma on MR imaging and differentiation from squamous cell carcinoma

1994 ◽  
Vol 10 (2) ◽  
pp. 7-13 ◽  
Author(s):  
Tsuyoshi Sawamura ◽  
Kazuyuki Minowa ◽  
Satoru Abe ◽  
Keiichi Ohmori ◽  
Yoichiro Hosokawa ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Mr Imaging ◽  
Cell Carcinoma ◽  
Adenoid Cystic Carcinoma ◽  
Squamous Cell ◽  
Adenoid Cystic

scholarly journals A case of esophageal collision tumor with adenoid cystic carcinoma and squamous cell carcinoma.

1989 ◽  
Vol 22 (8) ◽  
pp. 2072-2075
Author(s):  
Hiroyuki KOBAYASHI ◽  
Norimasa YOSHIDA ◽  
Hirotaka MARUYAMA ◽  
Takehiro HACHISUKA ◽  
Toshihiro MORI ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Adenoid Cystic Carcinoma ◽  
Squamous Cell ◽  
Collision Tumor ◽  
Adenoid Cystic

scholarly journals Primary tracheal tumours: 21 years of experience at Peking Union Medical College, Beijing, China

2008 ◽  
Vol 122 (11) ◽  
pp. 1235-1240 ◽  
Author(s):  
L Zhengjaiang ◽  
T Pingzhang ◽  
Z Dechao ◽  
G Reddy-Kolanu ◽  
V Ilankovan
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Adenoid Cystic Carcinoma ◽  
Squamous Cell ◽  
Survival Rates ◽  
Distant Metastases ◽  
Treatment Method ◽  
Malignant Tumours ◽  
Medical College ◽  
Adenoid Cystic

AbstractObjectives:To review our experience of the treatment of primary tracheal tumours.Study design:All medical notes of patients with primary tracheal tumours diagnosed between 1981 and 2002 were retrospectively analysed.Results:In this period, 80 patients were diagnosed with primary tracheal malignancy, 48 males and 32 females. The median age was 48 years. Sixty-nine patients had malignant tumours, most commonly adenoid cystic carcinoma (50.7 per cent) or squamous cell carcinoma (30.4 per cent). Fifty-five patients underwent surgery, 30 of whom also received radiotherapy. Twenty-five patients received only radiotherapy. The five-year survival rate for all malignant tumours was 30.5 per cent. The five-year survival rates for adenoid cystic carcinoma and squamous cell carcinoma were 40.2 and 24.6 per cent, respectively. Local recurrence and distant metastases developed in 21 patients (30.4 per cent).Conclusion:Primary tracheal tumours are rare and mainly malignant. Surgery is the most effective treatment method. Technical advances allow for safe resection of the tumour with a safe, tension-free anastomosis.

Aberrant cytokine expression in serum of patients with adenoid cystic carcinoma and squamous cell carcinoma of the head and neck

Head & Neck ◽  
2007 ◽  
Vol 29 (5) ◽  
pp. 472-478 ◽  
Author(s):  
Thomas K. Hoffmann ◽  
Eniko Sonkoly ◽  
Bernhard Homey ◽  
Katrin Scheckenbach ◽  
Christian Gwosdz ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Cell Carcinoma ◽  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Cytokine Expression ◽  
Adenoid Cystic

800 A phase I dose escalation and expansion study of intratumorally administered CV8102 as a single-agent or in combination with anti-PD-1 antibodies in patients with advanced solid tumors

2020 ◽  
Vol 8 (Suppl 3) ◽  
pp. A849-A849
Author(s):  
Thomas Eigentler ◽  
Lucie Heinzerling ◽  
Jürgen Krauss ◽  
Carsten Weishaupt ◽  
Peter Mohr ◽  
...  
Keyword(s):  
Squamous Cell Carcinoma ◽  
Phase I ◽  
Cell Carcinoma ◽  
Adenoid Cystic Carcinoma ◽  
Head And Neck ◽  
Squamous Cell ◽  
Dose Escalation ◽  
Single Agent ◽  
List Type ◽  
Adenoid Cystic

BackgroundCV8102 is a non-coding, non-capped RNA complexed with a carrier peptide activating the innate (via TLR7/8, RIG-I) and adaptive immune system.1 2 An ongoing phase I trial is investigating i.t. CV8102 either as a single agent or in combination with systemic anti-PD-1 antibodies in patients with advanced melanoma (MEL), squamous cell carcinoma of the skin (cSCC) or head and neck (hnSCC) and adenoid cystic carcinoma (ACC).MethodsAn open-label, cohort-based, dose escalation and expansion study in patients with advanced cutaneous melanoma (cMEL), cutaneous squamous cell carcinoma (cSCC), head and neck squamous cell carcinoma (hnSCC) or adenoid cystic carcinoma (ACC) is ongoing investigating i.t. CV8102 as single agent and in combination with anti-PD-1 antibodies.8 intratumoral injections of CV8102 are being administered initially over a 12 week period, while patients benefiting from the single agent therapy may receive further treatment. In an initial dose escalation part the maximum tolerated dose and recommended phase 2 dose for subsequent cohort expansion will be defined.ResultsAs of September 16, 2020, 29 patients have been treated with CV8102 as a single agent (25-900 µg) and 21 patients have received CV8102 (25-900 µg) in combination with anti-PD-1 antibodies. Most frequent treatment related adverse events were mild to moderate fever, fatigue, chills and headache. One patient treated at the 900 µg single agent experienced a dose limiting toxicity (G3 transaminase increase in the context of G2 cytokine release syndrome).Regression of injected and distant noninjected lesions was observed in several patients in the single agent and the anti-PD-1 combination cohorts. Updated safety and efficacy results will be presented.ConclusionsCV8102 showed an acceptable tolerability and preliminary evidence of clinical efficacy as single agent and in combination with anti-PD-1- antibodies.Trial RegistrationNCT03291002Ethics ApprovalThe study was approved by the Central Ethics Committees in Tuebingen, Germany under 785/2016AMG1, in France under 19.05.17.64111, in Barcelona, Spain under the EudraCT number.ConsentWritten informed consent was obtained from the patient for publication of this abstract and any accompanying images. A copy of the written consent is available for review by the Editor of this journal.ReferencesZiegler A, Soldner C, Lienenklaus S, Spanier J, Trittel S, Riese P, Kramps T, Weiss S, Heidenreich R, Jasny E, Guzmán CA, Kallen KJ, Fotin-Mleczek M, Kalinke U. A new RNA-based adjuvant enhances virus-specific vaccine responses by locally triggering TLR- and RLH-dependent effects. J Immunol 2017;198(4):1595-1605. doi:10.4049/jimmunol.1601129Heidenreich R, Jasny E, Kowalczyk A, Lutz J, Probst J, Baumhof P, Scheel B, Voss S, Kallen KJ, Fotin-Mleczek M. A novel RNA-based adjuvant combines strong immunostimulatory capacities with a favorable safety profile. Int J Cancer 2015 Jul 15;137(2):372-84. doi: 10.1002/ijc.29402

Sign in / Sign up

Export Citation Format

Share Document